SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug AdministrationDose-proportional increase in exposure observed in multiple ascending dose (MAD) expansion cohort with NMRA-511 (V1aR antagonist), suggesting potential to build on the efficacy profile demonstrated in P…

NMRA

Related stories